

## Key Information for Trusts/Hospitals

**DISCLAIMER:** FOR HEALTHCARE PROFESSIONALS IN UK **ONLY** WHO HAVE OR PLAN TO PRESCRIBE TEPLIZUMAB.



**HealthNet** is the sole provider for this Sanofi Homecare patient programme

### OBJECTIVES OF PROGRAMME

- Designed with patient experience in mind to support patients' compliance and experiences on teplizumab
- Reduce the patient/caregiver logistical barriers associated with a consecutive 14-day infusion to promote equitable access to treatment

### THE PROGRAMME WILL INCLUDE UP TO 9 DAYS (DAYS 6-14) OF:

1. **Dispense and Delivery** of the appropriate volume of the product to the patient's home and associated ancillary items required for administration.
2. **Nurse administration** of the product by a suitably qualified, licensed, and trained infusion nurse according to the care plan agreed between Healthnet and relevant treating HCP.
3. **Patient Resources** provision to support end to end journey of patients and caregivers utilising the service.

Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14



**Hospital**



**Hospital And / Or Homecare**




- **Days 1-5:** Treatment to take place in hospital/treating centre
- **Days 6-14:** Treatment in Homecare for up to 9 days

## NEXT STEPS & REFFERAL

### A SERVICE LEVEL AGREEMENT (SLA) BETWEEN HEALTHNET AND YOUR TRUST WILL BE REQUIRED TO ONBOARD PATIENTS ONTO THIS SANOFI FUNDED HOMECARE PROGRAMME

Should you wish to onboard your trust/hospital on this service. Here are the next steps:

- **Consent:** Following your consent, your Sanofi representative refers you to Healthnet team
- **Referral:** Healthnet's area manager reaches out to you or your clinical team / homecare pharmacy / procurement team to discuss the programme and next steps.
- **The SLA is signed:** Agreement is directly between HealthNet and your Trust only - Sanofi does not have access to the SLA contents
- **Documentation provided & Clinical Activation Meeting:** Once SLA is signed, HealthNet provides all necessary registration forms and prescription forms and tools for the service. You may also take part in a Clinical Activation Meeting with HealthNet to discuss protocols and communication channels for the delivery of the service
- **Go Live:** HealthNet will advise your trust and team when the service can go live.



## CONTACT US

Want to discuss further or request your referral onto HealthNet?

Contact your Sanofi **NHS Engagement Manager**

**Don't know who to email?**

Email [NEMGenMed@sanofi.com](mailto:NEMGenMed@sanofi.com)

▼ Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to [UK-drugsafety@sanofi.com](mailto:UK-drugsafety@sanofi.com)